Given these results, we concluded that TCTP itself was sufficient to promote the non-T cell-inflamed immune-phenotype and resistance of tumor cells to CTL killing, thereby contributing to anti-PD-L1 therapy resistance. The gene discussed is CD274; the disease is neoplasm.